<div id="readability-page-1"><p>Jones Trading started coverage on shares of <span>Septerna (NASDAQ:SEPN - Get Free Report)</span> in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set a &#34;buy&#34; rating and a $43.00 price target on the stock. Jones Trading's target price suggests a potential upside of 45.91% from the stock's previous close.</p><ul><li>Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead</li></ul><p>A number of other equities research analysts have also recently weighed in on the company. Raymond James Financial began coverage on shares of Septerna in a report on Friday. They set a &#34;strong-buy&#34; rating and a $38.00 price objective on the stock. Wall Street Zen upgraded shares of Septerna from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Septerna in a research note on Wednesday, October 8th. HC Wainwright boosted their price target on Septerna from $26.00 to $30.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, November 11th. Finally, Wells Fargo &amp; Company raised Septerna from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and lifted their target price for the company from $18.00 to $28.00 in a research report on Friday, November 14th. One analyst  has rated the stock with a Strong Buy rating, five have assigned  a Buy rating and one  has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $33.00.</p><p><b>View Our Latest Stock Analysis on Septerna</b></p><h2>Septerna Trading Down 0.4%</h2><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p>Septerna stock opened at $29.47 on Tuesday. Septerna has a 1-year low of $4.17 and a 1-year high of $30.50. The company has a market capitalization of $1.32 billion, a P/E ratio of -19.52 and a beta of 3.76. The firm's fifty day simple moving average is $23.87 and its 200-day simple moving average is $17.10. </p><p>Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.19 by ($0.28). The company had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%.  On average, equities research analysts predict that  Septerna will post -7.11 earnings per share for the current year. </p><h2>Insider Activity</h2><ul><li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li></ul><p>In related news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the sale, the senior vice president directly owned 92,911 shares of the company's stock, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.30% of the stock is currently owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently made changes to their positions in the company. BVF Inc. IL boosted its holdings in  Septerna by 79.3% in the 1st quarter. BVF Inc. IL now owns 4,396,124 shares of the company's stock valued at $25,454,000 after purchasing an additional 1,944,100 shares during the period.  Checkpoint Capital L.P. purchased a new position in  Septerna in the 1st quarter worth approximately $4,776,000.  ADAR1 Capital Management LLC purchased a new position in shares of  Septerna in the first quarter worth $4,174,000.  Perceptive Advisors LLC bought a new position in shares of  Septerna during the second quarter valued at about $5,723,000.  Finally, VR Adviser LLC purchased a new stake in  Septerna in the 2nd quarter worth approximately $5,713,000. </p><h2>About Septerna</h2> (Get Free Report)<p>We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.</p><h2>See Also</h2><ul><li>Five stocks we like better than Septerna</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Do you know what Amazon is planning for January 1?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0VQTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0VQTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Septerna Right Now?</h2><p>Before you consider Septerna, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.</p><p>While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SEPN

<p>Jones Trading initiated coverage on Septerna (NASDAQ:SEPN) with a "buy" rating and a $43.00 target price, suggesting a 45.91% upside. Other analysts have varied ratings, with a consensus "Moderate Buy" and a $33.00 target. Septerna's stock opened at $29.47, with a market cap of $1.32 billion. The company focuses on GPCR therapies in endocrinology, immunology, and metabolic diseases.</p>

Septerna (NASDAQ:SEPN) Coverage Initiated at Jones Trading